Evidence map›Paper›PMID 33812943›Full record

ArticleJournal of virological methods2021

Development and performance evaluation of the first in-house multiplex rRT-PCR assay in Bangladesh for highly sensitive detection of SARS-CoV-2.

Farjana Akther Noor, Kazi Sarjana Safain, Md Walid Hossain, Khalid Arafath, Kaiissar Mannoor, Mazbahul Kabir

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Journal of virological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Farjana Akther NoorDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, 1000, Bangladesh; Department of Biochemistry & Molecular Biology, Tejgaon College, Tejgaon, Dhaka, 1215, Bangladesh.
Kazi Sarjana SafainMolecular Division, OMC Healthcare (Pvt.) Ltd, Rupnagar, Dhaka, 1216, Bangladesh.
Md Walid HossainMolecular Division, OMC Healthcare (Pvt.) Ltd, Rupnagar, Dhaka, 1216, Bangladesh.
Khalid ArafathMolecular Division, OMC Healthcare (Pvt.) Ltd, Rupnagar, Dhaka, 1216, Bangladesh.
Kaiissar MannoorInfectious Diseases Laboratory, Institute for Developing Science and Health Initiatives, Mohakhali, Dhaka, 1212, Bangladesh.
Mazbahul KabirMolecular Division, OMC Healthcare (Pvt.) Ltd, Rupnagar, Dhaka, 1216, Bangladesh. Electronic address: mazbahul.kabir@omcbd.com.
Bangladesh Institute of Development Studies · BDOmron (Japan) · JPUniversity of Dhaka · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is posing a great threat to global health and economy. Due to the lack of broad diagnostic setup, consistent reagent supply lines, and access to laboratory instruments and equipment, it is undoubtedly an enormous burden for developing countries to face the crisis.

objectivesTo develop a cost-effective, reliable and sensitive multiplex assay for SARS-CoV-2 screening which would expand the testing capacities of a developing and low-income country like Bangladesh. STUDY

designInitially a singleplex and then a multiplex real-time reverse-transcriptase PCR assays were developed targeting 2 nucleocapsid genes of SARS-CoV-2, and the human RNase P gene as an internal control using laboratory-made mastermixes. Three sets of primer- probes were designed for each of the target genes and one set was optimized for the final reaction set-up. Limit of detection, cross-reactivity and reproducibility were checked in order to assess the sensitivity and specificity of the assays, and validation was done using clinical specimens.

resultsClinical evaluation of the new assays using 240 nasopharyngeal swabs showed 100 % sensitivity, specificity, and accuracy in detecting SARS-CoV-2 infection in human. Equal efficiency and concordant results were observed between the singleplex and multiplex approaches. Notably, the kit was able to detect SARS-CoV-2 RNA at very low concentration upto 5 copies/reaction.

conclusionThis is the first locally developed multiplex rRT-PCR kit in Bangladesh providing rapid and low-cost screening of COVID-19 which would be valuable for infection prevention and clinical management in the perspective of Bangladesh.

Indexed as

COVID-19COVID-19 Nucleic Acid TestingHumansLimit of DetectionMultiplex Polymerase Chain ReactionReagent Kits, DiagnosticReproducibility of ResultsSARS-CoV-2Sensitivity and SpecificityReagent Kits, DiagnosticCost effective assayDeveloping countryIn-house kitMultiplex rRT-PCRSARS-CoV-2Singleplex rRT-PCR

Identifiers

PMID33812943
PMCPMC8015390
OpenAlexW3146118702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.